American CryoStem and Rutgers University File Joint Patent on Stem Cell Platform

Apr 10, 2014
By BioPharm International Editors

Biotechnology developer American CryoStem and Rutgers University have partnered in a jointly owned patent application on adipose-derived stem-cell platform technology. The patent application follows a series of agreements between American CryoStem and research scientists at Rutgers University.

The initial collaboration between Rutgers and American CryoStem focused on using the company’s proprietary ATCELL (Adipose-Derived Stem Cells [ADSCs]) and patented ACSelerate (animal serum free), GMP-grade, cell-culture and differentiation mediums to enhance multi-functional nanotechnology and biomaterial platforms (NanoScript) created by KiBum Lee, PhD, Professor of Chemistry & Chemical Biology at Rutgers. According to the company, the combined technologies can be used to treat a wide range of degenerative diseases and orthopedic injuries.

NanoScript is based on the combination of nanosized particles including gold and other unique FDA-approved biomaterials, with a series of predetermined peptides and binding domains in specific ratios to create a synthetic transcription factor capable of differentiating hADSCs without introducing a virus or altering the cells’ DNA. American CryoStem stated, in a press release, that the multi-functional platform works with the company’s proprietary products to create any cell type including, but not limited to, muscle, cartilage, bone, adipocyte, neural, and induced pluripotent cells (IPSCs) that are a genetic match for the donor. The company believes that this technology provides an opportunity to create a series of cellular therapy applications to treat chronic disease and traumatic injury, while overcoming genetic hurdles associated with generic cellular therapies.

“Rutgers University and Dr. Lee’s extensive research experience with nanotechnology-inspired stem cell differentiation technologies and their application of American CryoStem’s proprietary ATCELL and ACSelerate products  have served to create a synergistic platform capable of dramatically increasing targeted point-of-care delivery of specific regenerative medicine therapies,” stated Anthony Dudzinski, Chief Operating Officer of American CryoStem, in a press release.

“Our collaboration with American CryoStem has allowed us to complete our ADSC-NanoScript technology platform and to advance our research to produce the repeatable results necessary for clinical development and FDA submission,” stated Dr. Lee in the press release.

The Rutgers-American CryoStem collaboration has focused on the regeneration of muscle cells for the repair of muscle loss. Further applications such as nerve repair for systemic disease and traumatic injuries are in the initial stages of development.

Source: American CryoStem